

74 - References

References

82 The Maudsley® Prescribing Guidelines in Psychiatry CHAPTER 1 References

1. Mallikaarjun S, et al. Pharmacokinetics, tolerability and safety of aripiprazole once-monthly in adult schizophrenia: an open-label, parallel-arm, multiple-dose study. *SchizophrRes* 2013; 150:281-288.
2. Correll CU, et al. Pharmacokinetic characteristics of long-acting injectable antipsychotics for schizophrenia: an overview. *CNS Drugs* 2021; 35:39-59.
3. Wang Y, et al. Population pharmacokinetics and dosing simulations for aripiprazole 2-month ready-to-use long-acting injectable in adult patients with schizophrenia or bipolar I disorder. *Clin Pharmacol Drug Dev* 2024; 13:631-643.
4. Otsuka Pharmaceutical Co Ltd. Highlights of Prescribing Information. ABILIFY ASIMTUFII® (aripiprazole) extended-release injectable suspension for intramuscular use. 2023 (last accessed November 2024); https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/217006s000lbl.pdf.
5. Harlin M, et al. A randomized, open-label, multiple-dose, parallel-arm, pivotal study to evaluate the safety, tolerability, and pharmacokinetics of aripiprazole 2-month long-acting injectable in adults with schizophrenia or bipolar I disorder. *CNS Drugs* 2023; 37:337-350.
6. Baune BT. Aripiprazole 2-month ready-to-use 960 mg (Ari 2MRTU): review of its possible role in schizophrenia therapy. *Curr Med Res Opin* 2024; 40:87-96.
7. Alkermes Inc. ARISTADA INITIO™ (aripiprazole lauroxil) extended-release injectable suspension [product monograph]. 2020 (last accessed February 2025); <https://www.aristadacaresupport.com/downloadables/ARISTADA-INITIO-ARISTADA-Payer--Hospital-Monograph.pdf>.
8. Jann MW, et al. Clinical pharmacokinetics of the depot antipsychotics. *Clin Pharmacokinet* 1985; 10:315-333.
9. Bailey L, et al. Estimating the optimal dose of flupentixol decanoate in the maintenance treatment of schizophrenia: a systematic review of the literature. *Psychopharmacology* 2019; 236:3081-3092.
10. Simpson GM, et al. Single-dose pharmacokinetics of fluphenazine after fluphenazine decanoate administration. *J Clin Psychopharmacol* 1990; 10:417-421.
11. Balant-Gorgia AE, et al. Antipsychotic drugs: clinical pharmacokinetics of potential candidates for plasma concentration monitoring. *Clin Pharmacokinet* 1987; 13:65-90.
12. Gitlin MJ, et al. Persistence of fluphenazine in plasma after decanoate withdrawal. *J Clin Psychopharmacol* 1988; 8:53-56.

13. Heres S, et al. Pharmacokinetics of olanzapine long-acting injection: the clinical perspective. *Int Clin Psychopharmacol* 2014; 29:299–312.
14. Ravenstijn P, et al. Pharmacokinetics, safety, and tolerability of paliperidone palmitate 3-month formulation in patients with schizophrenia: a phase-1, single-dose, randomized, open-label study. *J Clin Pharmacol* 2016; 56:330–339.
15. Janssen Pharmaceuticals Inc. Highlights of Prescribing Information. INVEGA TRINZA® (paliperidone palmitate) extended-release injectable suspension for intramuscular use. 2024 (last checked November 2024); [https://www.janssenlabels.com/package--insert/product-monograph/ prescribing-information/INVEGA+TRINZA-pi.pdf](https://www.janssenlabels.com/package-insert/product-monograph/prescribing-information/INVEGA+TRINZA-pi.pdf).
16. Janssen Pharmaceuticals Ltd. Highlights of Prescribing Information: INVEGA HAFYERA™ (paliperidone palmitate) extended-release injectable suspension, for gluteal intramuscular use. 2021 (last checked November 2024); https://www.accessdata.fda.gov/drugsatfda_docs/label/2021/207946s010lbl.pdf.
17. Barnes TR, et al. Long-term depot antipsychotics. A risk-benefit assessment. *Drug Saf* 1994; 10:464–479.
18. Ogden DA, et al. Determination of pipothiazine in human plasma by reversed-phase high-performance liquid chromatography. *J Pharm Biomed Anal* 1989; 7:1273–1280.
19. US Center for Drug Evaluation and Research. Clinical Pharmacology and Biopharmaceutics Review(s). PERSERIS (Risperidone, RBP-7000, Risperidone ATRIGEL). 2018 (last checked February 2025); https://www.accessdata.fda.gov/drugsatfda_docs/nda/2018/210655Orig1s000Cl inPharmR.pdf.
20. Shandong Luye Pharmaceutical Co Ltd. Highlights of Prescribing Information. RYKINDO® (risperidone) for extended-release injectable suspension for intramuscular use. 2023 (last checked November 2024); https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/212849s000lbl.pdf.
21. Walling DP, et al. Pharmacokinetics and safety of a novel extended-release microsphere formulation of risperidone in patients with schizophrenia or schizoaffective disorder. *J Clin Pharmacology* 2024; doi: 10.1002/jcph.6143.
22. Laboratorios Farmacéuticos Rovi S A Madrid Spain. Highlights of Prescribing Information. RISVAN® (risperidone) for extended-release injectable suspension for intramuscular use. 2024 (last checked November 2024); https://www.accessdata.fda.gov/drugsatfda_docs/label/2024/214835s000lbl.pdf.
23. Laveille C, et al. Development of a population pharmacokinetic model for the novel long-acting injectable antipsychotic risperidone ISM®. *Br J Clin Pharmacol* 2024; 90:2256–2270.
24. Teva Neuroscience Inc. Highlights of Prescribing Information. UZEDY (risperidone) extended-release injectable suspension for subcutaneous use. 2023 (last checked November 2024); https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/213586s000lbl.pdf.
25. Viala A, et al. Comparative study of the pharmacokinetics of zuclopenthixol decanoate and fluphenazine decanoate. *Psychopharmacology (Berl)* 1988; 94:293–297.
26. Soni SD, et al. Plasma levels of fluphenazine decanoate. Effects of site of injection, massage and muscle activity. *Br J Psychiatry* 1988; 153:382–384.

Revision #1

Created 2026-01-04 20:13:55 UTC by Omar Ayman

Updated 2026-01-04 20:13:55 UTC by Omar Ayman